The effect of topical bevacizumab on corneal neovascularization.
OBJECTIVE
To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.


METHODS
Prospective, nonrandomized, masked observational case series.


METHODS
Ten eyes of 7 patients with corneal NV.


METHODS
Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.


METHODS
Corneal NV and changes in ophthalmic evaluations.


RESULTS
Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.


CONCLUSIONS
Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.
Kim
Sang Woo
SW
Corneal Dystrophy Research Institute, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Ha
Byung Jin
BJ
Kim
Eung Kweon
EK
Tchah
Hungwon
H
Kim
Tae-im
TI
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D019573:Epithelium, Corneal / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab